UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Jun. 30, 2012	Jul. 02, 2011
Cash Flows from Operating Activities:
Net income	$ 9,787	$ 16,947
Non cash items:
Depreciation and amortization	11,180	11,988
Stock compensation expense	2,417	2,401
Loss on sales of property, plant and equipment	110	56
Unrealized loss from hedging activities	568	609
Accretion of interest expense on contingent consideration income	0	89
Change in operating assets and liabilities:
Decrease in accounts receivable, net	8,020	7,939
Increase in inventories	(17,040)	(10,288)
(Increase) in prepaid income taxes	(455)	7,993
(Increase)/decrease in other assets and other long-term liabilities	(5,479)	(3,059)
Tax benefit on exercise of stock options	1,050	356
Decrease in accounts payable and accrued expenses	(9,605)	(7,900)
Net cash provided by operating activities	553	27,131
Cash Flows from Investing Activities:
Purchase of property, plant and equipment	(8,441)	(11,801)
Proceeds from sale of property, plant and equipment	252	19
Investment in Hemerus	(1,000)	0
Net cash used in investing activities	(9,189)	(11,782)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(217)	(361)
Net increase/(decrease) in short-term loans	(18)	(9)
Proceeds from employee stock purchase plan	2,105	1,849
Proceeds from exercise of stock options	13,246	2,675
Excess tax benefit on exercise of stock options	1,111	313
Net cash provided by financing activities	16,227	4,467
Effect of exchange rates on cash and cash equivalents	(405)	368
Net increase in Cash and Cash Equivalents	7,186	20,184
Cash and Cash Equivalents at Beginning of the period	228,861	196,707
Cash and Cash Equivalents at End of the Period	236,047	216,891
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	7,236	3,150
Supplemental Disclosures of Cash Flow Information:
Interest paid	84	102
Income taxes paid	$ 3,194	$ 1,387